Cost‐effectiveness of vorasidenib in treatment of isocitrate dehydrogenase–mutated low‐grade glioma
Cancer · 01.06.2026 · 132 (11)
DOI: 10.1002/cncr.70463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 20.05.2026. Verfasst von Adam C Kessel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Brain Neoplasms, Triazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Vorasidenib is Food and Drug Administration‐approved for treatment of grade 2 isocitrate dehydrogenase (IDH)–mutant gliomas and has demonstrated a benefit in progression‐free survival compared to a placebo. This study assessed the cost‐effectiveness of this treatment strategy compared to standard treatment: observation or chemoradiation (CRT).
Methods
The authors used an integrated Markov model to compare quality‐adjusted life‐years (QALY) gained and cost‐effectiveness of patients with IDH‐mutated low‐grade glioma (LGG) treated with vorasidenib, observation, or CRT. Outcomes were expressed as incremental cost‐effectiveness ratios (ICERs) per QALY gained. Treatment is considered cost‐effective if it meets the commonly accepted willingness‐to‐pay threshold of $100,000 per QALY gained.
Results
Based on model parameters, vorasidenib demonstrated an ICER of $356,756 per QALY when compared to CRT. When compared to observation, vorasidenib demonstrated an improved ICER of $215,191 per QALY. On one‐way sensitivity analysis compared to observation, median cost of vorasidenib and median overall survival were most likely to affect ICER with only marginal changes on analysis of other model factors. For ICER to become ≤$100,000 compared to observation, the cost of vorasidenib would need to drop to below $14,072 monthly or have a median survival gain of at least 11.9 years. The probabilistic sensitivity analysis demonstrated that vorasidenib was favored in none of 5000 Monte Carlo iterations.
Conclusion
Using the best available data, the current price of vorasidenib does not meet commonly accepted cost‐effectiveness thresholds in treatment of IDH‐mutated LGGs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Radiation Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Neuro-Oncology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Adam C Kessel, Paul D Brown, Bryan Neth, Ugur Sener, Mark Waddle, William G Breen, Roman O Kowalchuk
Zitieren
APA
Kessel, A. C., Kim, H., Brown, P. D., Lehrer, E. J., Laack, N. N., Mahajan, A., Yan, E., Schultz, S. E., Kizilbash, S., Neth, B., Sener, U., Waddle, M., Breen, W. G., & Kowalchuk, R. O. (2026). Cost‐effectiveness of vorasidenib in treatment of isocitrate dehydrogenase–mutated low‐grade glioma. Cancer, 132(11). https://doi.org/10.1002/cncr.70463
Vancouver
Kessel AC, Kim H, Brown PD, Lehrer EJ, Laack NN, Mahajan A, et al. Cost‐effectiveness of vorasidenib in treatment of isocitrate dehydrogenase–mutated low‐grade glioma. Cancer. 2026;132(11). doi:10.1002/cncr.70463
BibTeX
@article{Kessel2026,
author = {Kessel, Adam C and Kim, Hayeon and Brown, Paul D and Lehrer, Eric J and Laack, Nadia N and Mahajan, Anita and Yan, Elizabeth and Schultz, Sydney E and Kizilbash, Sani and Neth, Bryan and Sener, Ugur and Waddle, Mark and Breen, William G and Kowalchuk, Roman O},
title = {Cost‐effectiveness of vorasidenib in treatment of isocitrate dehydrogenase–mutated low‐grade glioma},
journal = {Cancer},
year = {2026},
volume = {132},
number = {11},
doi = {10.1002/cncr.70463}
}
EUVIMED